{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-345732","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2026-08-12T11:15:20+00:00","discovered_at":"2026-08-12T11:20:00.474422+00:00","generated_at":"2026-08-12T11:20:14.573401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TScan Q2 net loss narrows to $30.4M; first patient dosed in Phase 3 ALLOHA-2 trial","bullets":["Q2 2026 net loss $30.4M vs $37.0M; revenue $1.1M vs $3.1M, down on Amgen collaboration timing.","Cash $100.2M at 6/30/26 funds ops into Q2 2027; missed debt milestones trigger term loan amortization from Q4 2026.","First patient dosed in Phase 3 ALLOHA-2 (TSC-101, heme malignancies); topline expected mid-2028.","Cohort C ALLOHA data: 79% (11/14) complete donor chimerism ~3 weeks post-TSC-101; ~90% (17/19) first-pass manufacturing success.","TSC-102-A01 and TSC-102-A03 Phase 1 trials expected Q4 2026; solid-tumor IND roadmap by H2 2027 after FDA INTERACT engagement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-345732","json":"https://secwatch.observer/filing/0001193125-26-345732.json","markdown":"https://secwatch.observer/filing/0001193125-26-345732.md","text":"https://secwatch.observer/filing/0001193125-26-345732.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526345732/0001193125-26-345732-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526345732/tcrx-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T11:20:14.573401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}